The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such ...

Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and ...

Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...

The central theme was moving beyond a lens-centric approach to vision, historically the foundation of presbyopia research, ...

Apellis Pharmaceuticals recently announced post hoc analysis data of the GALE extension study. This new data is the result of ...

The timeline for the proposed Alcon acquisition of STAAR Surgical has once again been extended as STAAR announced amendments ...

Paul Badawi, Founder and CEO of Sight Sciences and Leon Herndon, MD, Duke University Eye Center, Durham, NC, commented on the ...

Inder Paul Singh, a glaucoma anterior segment surgeon from southeastern Wisconsin, presented his clinical experience and a ...

OCT has transformed retinal practice, enhancing diagnostic accuracy and treatment efficiency while reducing reliance on ...

Trattler: Patients with severe dry eye can in some cases be exceptionally challenging, and it can feel as if therapies are ...